Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases

Acta Clinica Croatica

Volumn 51, Issue 4, 2012, Pages 673-683

  Bašić Kes, Vanja ^a   Kes, Petar ^b   Zavoreo, Iris ^a   Lisak, Marijana ^a   Zadro, Lucija ^a   Ćorić, Lejla ^a   Demarin, Vida ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Intravenous immunoglobulin; Neurologic diseases

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; CREATINE KINASE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; IMMUNOLOGIC FACTOR;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADD ON THERAPY; ALZHEIMER DISEASE; ARTICLE; CEREBELLUM DEGENERATION; CHRONIC KIDNEY FAILURE; DAILY LIFE ACTIVITY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DYSPNEA; EATON LAMBERT SYNDROME; EPILEPSY; ERYTHEMA; FEVER; FOLLOW UP; GUILLAIN BARRE SYNDROME; HEMATURIA; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; MAINTENANCE DRUG DOSE; MENINGISM; META ANALYSIS (TOPIC); MONONEUROPATHY; MORTALITY; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; MYASTHENIA GRAVIS; MYOKYMIA; NARCOLEPSY; NAUSEA; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PARAPROTEINEMIA; PELIZAEUS MERZBACHER DISEASE; PLASMAPHERESIS; POLYMYOSITIS; POLYRADICULONEUROPATHY; POSTPOLIOMYELITIS SYNDROME; PRACTICE GUIDELINE; PROGNOSIS; PUERPERIUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RETROSPECTIVE STUDY; SIDE EFFECT; STIFF MAN SYNDROME; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEST SYNDROME;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; NERVOUS SYSTEM DISEASES;

EID: 84884971931     PISSN: 03539466     EISSN: 13339451     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. ELOVAARA I, APOSTOLSKI S, van DOORN P, GIL-HUS NE, HIETAHARjU A, HONKANIEMI j, VAN SCHAIK IN, SCOLDING N, SOELBERG SORENSEN P, UDD B. EFNS guidelines for the use of intravenous im-munoglobulin in treatment of neurological diseases. Eur j Neurol 2008;15:893-908.
2. KAZATCHKINE MD, KAVERI SV. Immunomodulation of autoimmune and infammatory diseases with intravenous immune globulin. N Engl j Med 2001;345:747-55.
3. BASTA M, DALAKAS MC. High-dose intravenous im-munoglobulin exerts its benefcial efects in patients with der-matomyositis by blocking endomysial deposition of activated complement fragments. j Clin Invest 1994;94:1729-35.
4. GOLD R, STANGEL M, DALAKAS MC. Drug Insight: the use of intravenous immunoglobulin in neurology - thera-peutic considerations and practical issues. Nature Clin Pract Neurol 2007;3:36-44.
5. MASSON PL. Elimination of infectious antigens and in-crease of IgG catabolism as possible modes of action of IVIG. j Autoimmun 1993;6:683-9.
6. SHARMA M, KES P, BAšIĆ-KES V, NIKOLIĆ-HEITZLER V, DEMARIN V, PODOBNIK-šARKANjI S. Guillain-Barré syndrome in a patient sufering acute myo-cardial infarction. Acta Clin Croat 2002;41:255-7.
7. WINER jB, HUGHES RAC, OSMOND C. A prospective study of acute idiopathic neuropathy. I Clinical features and their prognostic value. j Neurol Neurosurg Psychiatry 1988;51:605-12.
8. BRETTLE RP, GROSS M, LEGG Nj, et al. Treatment of acute polyneuropthy by plasma exchange. Lancet 1978;2:1100.
9. Te Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-104.
10. Consensus Conference. Te utility of therapeutic plasma-pheresis for neurological disorders. NIH Consensus Development. jAMA 1986;256:1333-7.
11. KLEyWEG RP, Van der MECHE FGA, MEULSTEE j. Treatment of Guillain-Barré syndrome with high-dose gam-maglobulin. Neurology 1988;38:1639-41.
12. Van der MECHE FGA, SCHMITZ PIM, Te Dutch Guil-lain-Barré Study Group. A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome. N Engl j Med 1992;326:1123-9.
13. NOMURA K, HAMAGUCHI K, HATTORI T, et al. A randomized controlled trial comparing intravenous immu-noglobulin and plasmapheresis in Guillain-Barré syndrome. Neurol Ter 2001;18:69-81.
14. GüRSES N, UySAL S, CnetNKAyA F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand j Infect Dis 1995;27:241-3.
15. WANG R, FENG A, SUN W, WEN Z. Intravenous immu-noglobulin in children with Guillain-Barré syndrome. j App Clin Pediatr 2001;16:223-4.
16. KORINTHENBERG R, SCHESSL j, KIRSCHNER j, et al. Intravenous immunoglobulin in the treatment of childhood Guillain-Barré syndrome. Pediatrics 2005;116:8-14.
17. HUGHES RAC, CORNBLATH DR. Guillain-Barré syn-drome. Lancet 2005;366:1653-66.
18. HAHN AF, et al. Intravenous immunoglobulin treatment in chronic infammatory demyelinating polyneuropathy - a double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-77.
19. HUGHES R, et al. Randomized controlled trial of intra-venous immunoglobulin versus oral prednisolone in chronic infammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
20. MENDELL jR, et al. Randomized controlled trial of IVIg in untreated chronic infammatory demyelinating polyradic-uloneuropthy. Neurology 2001;56:445-9.
21. HUGHES RAC, BOUCHE P, CORNBLATH DR, et al. EFNS/PNS guideline on management of chronic infam-matory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Socinetes and the Peripheral Nerve Society. Eur j Neurol 2006;13:326-32.
22. CARPO M, CAPELLARI A, MORA G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998;50:1380-2.
23. Van der BERG LH, LOKHORST H, WOKKE jH. Pulsed high-dose dexamethasone is not efective in patients with multifocal motor neuropathy (comment). Neurology 1997;48:1135.
24. CLAUS D, SPECHT S, ZIESCHANG M. Plasmapheresis in multifocal motor neuropathy: a case report. j Neurol Neu-rosurg Psychiatry 2000;68:533-5.
25. FEDERICO P, ZOCHODNE DW, HAHN AF, et al. Multifocal motor neuropathy improved by IVIg: random-ized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
26. LEGER jM, CHASSANDE B, MUSSET L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-53.
27. Van den BERG LH, KERKHOFF H, OEy PL, et al. Treat-ment of multifocal motor neuropathy with high dose intra-venous immunoglobulins: a double blind, placebo controlled study. j Neurol Neurosurg Psychiatry 1995;59:248-52.
28. VUCIC S, BLACK KR, CHONG PST, CROS D. M u lt i f o c a l motor neuropathy. Decrease in conduction blocks and reinner-vation with long-term IVIg. Neurology 2004;63:1264-9.
29. van SCHAIK IN, BOUCHE P, ILLA I, et al. EFNS/PNS guideline on management of multifocal motor neuropathy. Report of a join task force of the European Federation of Neurological Socinetes and the Peripheral Nerve Society. Eur j Neurol 2006;13:802-8.
30. LATOV N. Pathogenesis and therapy of neuropathies as-sociated with monoclonal gammopathies. Ann Neurol 1995;37(S1):32-42.
31. LUNN MPT, NOBILE-ORAZIO E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associ-ated peripheral neuropathies. Cochrane Database of Systematic Reviews 2006:CD002827.
32. HADDEN RDM, NOBILE-ORAZIO E, SOMMER C, et al. Paraproteinaemic demyelinating neuropathy. In: HUGHES R, BRAININ M, GILHUS NE, editors. European handbook of neurological management. Blackwell Publishing, 2006;362-75.
33. ALLEN D, LUNN MPT, NIERMEIjER j, NOBILE-ORAZIO E. Treatment for IgG and IgA paraproteinae-mic neuropathy. Cochrane Database of Systematic Reviews 2007:CD005376.
34. MADDISON P, NEWSOM-DAVIS j. Treatment for Lam-bert-Eaton myasthenic syndrome. Cochrane Database of Systematic Reviews 2005;(2):CD003279.
35. ALESSI G, De REUCK j, De BLEECKER j, VAN-CAyZEELE S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg 2000;102:173-5.
36. ISHII A, HAyASHI A, OHKOSHI N, et al. Clinical evalu-ation of plasma exchange and high dose intravenous immu-noglobulin in a patient with Isaacs syndrome. j Neurol Neu-rosurg Psychiatry 1994;57:840-2.
37. MITCHELL WG, DAVALOS-GONZALEZ y, BRUMM VL, et al. Opsoclonus-ataxia caused by childhood neuroblas-toma: developmental and neurologic sequelae. Pediatrics 2002;109:86-98.
38. BATALLER L, GRAUS F, SAIZ A, VILCHEZ jj, Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myo-clonus. Brain 2001;2:437-43.
39. Al-M AyOU F SM, L A x ER R M, SCHNEIDER R , et al. Intravenous immunoglobulin therapy for juvenile dermatomyosi-tis - efcacy and safety. j Rheumatol 2000;27:2498-503.
40. SANSOME A, DUBOWITZ V. Intravenous immunoglob-ulin in juvenile dermatomyositis - four year review of nine cases. Arch Dis Childhood 1995;72:25-8.
41. TSAI Mj, LAI CC, LIN SC, et al. Intravenous immuno-globulin therapy in juvenile dermatomyositis. Zhonghua Min Guo xiao Erke yi xue Hui Za Zhi 1997;38:111-5.
42. DALAKAS MC, SONIES B, DAMBROSIA j, et al. Treat-ment of inclusion-body myositis with IVIG: a double-blind, placebo controlled study. Neurology 1997;48:712-6.
43. WALTER MC, LOCHMULLER H, TOEPFER M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. j Neurol 2000;247:22-8.
44. DALAKAS MC, KOFFMAN B, FUjII M, et al. A controlled study of intravenous immunoglobulin combined with predni-sone in the treatment of IBM. Neurology 2001;56:323-7.
45. CHERIN P, PELLnetER S, TEIxEIRA A, et al. Results and long-term follow up of intravenous immunoglobulin in-fusions in chronic, refractory polymyositis: an open study with thirty-fve adult patients. Arthritis Rheum 2002;46:467-74.
46. SKEIE GO, APOSTOLSKI S, EVOLI A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur j Neurol 2006;13:691-9.
47. GAjDOS P, CHEVRET S, TOyKA K. Intravenous im-munoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews 2006;(2).
48. FEASBy T, BANWELL B, BENSTEAD T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007;21:S57-S107.
49. FARBU E, GILHUS NE, BARNES M P , et al. E F NS g u id e -line on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur j Neurol 2006;13:795-801.
50. HALSTEAD LS. Assessment and diferential diagnosis for post-polio syndrome. Orthopedics 1991;14:1209-17.
51. GONZALEZ H, KHADEMI M, ANDERSSON M, et al. Prior poliomyelitis - IVIG treatment reduces proinfammatory cytokine production. j Neuroimmunol 2004;150:139-44.
52. FARBU E, REKAND T, VIK-MO E, LyGREN H, GIL-HUS NE, AARLI jA. Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur j Neurol 2007;14:60-5.
53. GONZALEZ H, SUNNERHAGEN KS, SjOBERG I, KAPONIDES G, OLSSON T, BORG K. Intravenous im-munoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurology 2006;5:493-500.
54. KAPONIDES G, GONZALEZ H, OLSSON T, BORG K. Efect of intravenous immunoglobulin in patients with post-polio syndrome - an uncontrolled pilot study. j Rehabil Med 2006;38:138-40.
55. FARBU E, REKAND T, GILHUS NE, et al. Intravenous immunoglobulin in postpolio syndrome. Tidsskr Nor Laege-foren 2004;124:2357-8.
56. ACHIRON A, GABBAy U, GILAD R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Efect on re-lapses. Neurology 1998;50:398-402.
57. FAZEKAS F, DEISENHAMMER F, STRASSER FUCHS S, NAHLER G, MAMOLI B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-93.
58. LEWANSKA M, ZAjDAL MS, SELMAj K. No diference in efcacy of two diferent doses of intravenous immuno-globulins in MS: clinical and MRI assessment. Eur j Neurol 2002;9:565-72.
59. SORENSEN PS, WANSCHER B, jENSEN CV, et al. In-travenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-81.
60. SORENSEN PS, FAZEKAS F, LEE M. Intravenous immu-noglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur j Neurol 2002;9:557-63.
61. FAZEKAS F, STRASSER-FUCHS S, HOMMES OR. Intravenous immunoglobulin in MS: promise or failure?. j Neurol Sci 2007;259:61-6.
62. HOMMES OR, SORENSEN PS, FAZEKAS F, et al. In-travenous immunoglobulin in secondary progressive mul-tiple sclerosis: randomised placebo-controlled trial. Lancet 2 0 0 4;36 4:1149-56.
63. HAAS j. High dose IVIG in the post partum period for prevention of exacerbations in MS. Multiple Sclerosis 2000;6(Suppl 2):S18-S20.
64. HAAS j, HOMMES OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mul-tiple Sclerosis 2007;13:900-8.
65. BAKKER j, METZ L. Devics neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can j Neurol Sci 2 0 0 4;31:265-7.
66. AIRAS L, KURKI T, ERjANTI H, MARTTILA Rj. Suc-cessful pregnancy of a patient with Balos concentric sclerosis. Multiple Sclerosis 2005;11:346-8.
67. NISHIKAWA M, ICHIyAMA T, HAyASHI T, OUCHI K, FURUKAWA S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol 1999;21:583-6.
68. FINSTERER j, GRASS R, STöLLBERGER C, MAMO-LI B. Immunoglobulins in acute parainfectious disseminated encephalomyelitis. Clin Pharmacol 1998;21:256-61.
69. SAHLAS Dj, MILLER SP, GUERIN M, VEILLEUx M, FRANCIS G. Treatment of acute disseminated encepha-lomyelitis with intravenous immunoglobulin. Neurology 2000;54:1370-2.
70. ANDERSEN jB, RASMUSSEN LH, HERNING M, PARREGAARD A. Dramatic improvement of severe acute disseminated encephalomyelitis after treatment with intra-venous immunoglobulin in a three-year-old boy. Dev Med Child Neurol 2001;43:136-40.
71. MARCHIONI E, MARINOU-AKTIPI K, UGGETTI C, BOTTANELLI M, PICHIECCHIO A, et al. Efectiveness of intravenous immunoglobulin treatment in adult patients with steroid resistant monophasic or recurrent acute disseminated encephalomyelitis. j Neurol 2002;249:100-4.
72. DALAKAS MC, FUjII M, LI M, et al. High-dose immune globulin for stif-person syndrome. N Engl j Med 2001;345:1870-6.
73. VILLANI F, AVANZINI G. Te use of immunoglobulins in the treatment of human epilepsy. Neurol Sci 2002;23(Suppl 1) : s 3 3 -7.
74. BILLIAU An D, WITTERS P, CEULEMANS B, KASTAN A, WOUTERS C, et al. Intravenous immuno-globulins in refractory childhood-onset epilepsy: efects on seizure frequency, EEG activity and cerebrospinal fuid cy-tokine profle. Epilepsia 2007;48:1739-49.
75. CAVAZZUTI GB. Infantile encephalopathies. Neurol Sci 2003;24:S244-S245.
76. DODEL R, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002;52:253-6.
77. DODEL RC, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. j Neurol Neurosurg Psychiatry 2004;75:1472-4.
78. SIEGEL jM, BOEHMER LN. Narcolepsy and the hypo-crnetn system - where motion meets emotion. Nat Clin Pract Neurol 2006;2:548-56.
79. DAUVILLIERS y, et al. Successful management of cata-plexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56:905-8.
80. DAUVILLIERS y, et al. Follow-up of four narcolepsy pa-tients treated with intravenous immunoglobulins. Ann Neu-rol 2006;60:153.
81. STANGEL M, KIEFER R, PETTE M, SMOLKA MR, MARx P, GOLD R. Side efects of intravenous immu-noglobulin in autoimmune neurological diseases. j Neurol 2003;250:818-21.